| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
FK-3657 targets the bradykinin (BK)-B2 receptor, a G protein-coupled receptor involved in inflammation, pain, and vasodilation. It acts as a non-peptide antagonist with IC50 values of 0.56 nM, 1.5 nM, and 2.9 nM for pig, rat, and human B2 receptors, respectively. The compound is orally bioactive.
|
|---|---|
| ln Vitro |
In vitro, FK-3657 potently antagonizes the bradykinin B2 receptor with IC50 values of 0.56 nM (pig), 1.5 nM (rat), and 2.9 nM (human). As a non-peptide antagonist, it blocks bradykinin-induced signaling through the B2 receptor. The compound demonstrates high affinity and selectivity for the B2 receptor over other bradykinin receptor subtypes.
|
| ln Vivo |
In vivo, FK-3657 is orally bioactive and has been studied for its immunomodulatory effects. It modulates T-cell responses and has been investigated for immune tolerance and immunosuppressive therapies. The compound's bradykinin B2 receptor antagonism may also produce anti-inflammatory and analgesic effects in vivo.
|
| Enzyme Assay |
The in vitro receptor binding assay for FK-3657 involves measuring its affinity for the bradykinin B2 receptor. Radiolabeled ligand binding assays are performed using membrane preparations from cells expressing B2 receptors from different species. Varying concentrations of FK-3657 are incubated with the receptor preparation, and binding affinity (IC50) is determined. FK-3657 shows IC50 values of 0.56 nM, 1.5 nM, and 2.9 nM for pig, rat, and human B2 receptors, respectively.
|
| Cell Assay |
In vitro cellular assays for FK-3657 involve treating cultured cells expressing bradykinin B2 receptors with varying concentrations of the compound. Bradykinin-induced calcium mobilization or other downstream signaling events are measured using fluorescent indicators. FK-3657's ability to block bradykinin-induced signaling is assessed. T-cell responses may be evaluated in immune cell cultures to assess immunomodulatory effects.
|
| Animal Protocol |
In vivo animal experiments for FK-3657 typically use rodent models of inflammation, pain, or immune response. The compound is administered orally at various doses. Inflammatory markers, pain responses, or immune cell activation are measured. FK-3657 has been studied for its effects on T-cell modulation and immune tolerance. Specific protocols are not extensively documented but would be established in immunology research.
|
| ADME/Pharmacokinetics |
FK-3657 is an orally bioactive bradykinin B2 receptor antagonist. The compound has a molecular weight of 592.47 (C30H27Cl2N5O4). As a small molecule, it is expected to have good oral bioavailability and reasonable tissue distribution. Specific PK parameters including half-life, Cmax, and metabolic pathways would be available from preclinical studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for FK-3657 are limited in publicly available sources. As an immunomodulatory agent targeting the bradykinin system, potential adverse effects may include those related to bradykinin pathway modulation, such as angioedema or hypotension. Complete toxicology studies including acute, repeated-dose, and genotoxicity assessments would be required for therapeutic development.
|
| References | |
| Additional Infomation |
FK-3657 (CAS#: 167838-64-4) is a non-peptide bradykinin B2 receptor antagonist also known as FR-173657. It has IC50 values of 0.56 nM, 1.5 nM, and 2.9 nM for pig, rat, and human B2 receptors, respectively. The compound is orally bioactive and has been studied for immunomodulatory effects, including T-cell modulation and immune tolerance. FK-3657 is not approved for clinical use.
|
| Molecular Formula |
C30H27CL2N5O4
|
|---|---|
| Molecular Weight |
592.472484827042
|
| Exact Mass |
591.144
|
| CAS # |
167838-64-4
|
| PubChem CID |
5311108
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
41
|
| Complexity |
939
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NC2=C(C=CC=C2OCC3=C(C=CC(=C3Cl)N(C)C(=O)CNC(=O)/C=C/C4=CN=C(C=C4)NC(=O)C)Cl)C=C1
|
| InChi Key |
XCKWRUGRUFVXGC-NTEUORMPSA-N
|
| InChi Code |
InChI=1S/C30H27Cl2N5O4/c1-18-7-10-21-5-4-6-25(30(21)35-18)41-17-22-23(31)11-12-24(29(22)32)37(3)28(40)16-34-27(39)14-9-20-8-13-26(33-15-20)36-19(2)38/h4-15H,16-17H2,1-3H3,(H,34,39)(H,33,36,38)/b14-9+
|
| Chemical Name |
(E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide
|
| Synonyms |
FK3657; FK 3657; FK-3657
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6878 mL | 8.4392 mL | 16.8785 mL | |
| 5 mM | 0.3376 mL | 1.6878 mL | 3.3757 mL | |
| 10 mM | 0.1688 mL | 0.8439 mL | 1.6878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
